VIDEO: Timdarpacept examined in dedicated chronic myelomonocytic leukemia trial
Click Here to Manage Email Alerts
In this video, Douglas Tremblay, MD, discusses the results of a study into a first-line treatment of chronic myelomonocytic leukemia presented at ESMO Congress 2024.
Tremblay, an assistant professor of medicine at the Icahn School of Medicine at Mount Sinai, highlighted the study, which was a phase 2 study into timdarpacept (IMM01, ImmuneOnco Biopharmaceuticals) in a dedicated chronic myelomonocytic leukemia (CMML) trial.
“These [findings] suggest that this sort of strategy could be explored in the future, but of course, we need randomized phase 3 trials, which are difficult to do in this disease, to really understand what the value add of timdarpacept is to azacitidine in CMML,” Tremblay said.
Collapse
Click Here to Manage Email Alerts